Qiming U.S. Ventures Management, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Qiming U.S. Ventures Management, LLC reported 6 stock positions worth $23.6 million. Its top holding was Tourmaline Bio (TRML) at 50.2% of the portfolio, followed by Jasper Therapeutics (JSPR, 21.8%) and Korro Bio (KRRO, 19.5%). Its holdings were unchanged from Q1 2025.
- Most Recent 13F
- Q3 2025
- Location
- BELLEVUE, WA
- CIK
- 0001909617
- Portfolio Value
- $23.6M (Q2 2025)
- SEC Filing
- 0001415889-25-021900 ↗ filed Aug 14, 2025
Holdings Value
Holdings 6 stocks · $23.6M
| TRML Tourmaline Bio Inc. | 50.22% | 741,691 | $11.9M | No change |
| JSPR Jasper Therapeutics Inc. | 21.83% | 928,964 | $5.2M | No change |
| KRRO Korro Bio Inc. | 19.47% | 368,085 | $4.6M | No change |
| VTYX Ventyx Biosciences Inc. | 3.74% | 412,225 | $882K | No change |
| HLVX Hillevax Inc. | 3.14% | 372,615 | $742K | No change |
| KZR Kezar Life Sciences Inc. | 1.61% | 82,871 | $380K | No change |
Portfolio Sells Q1 2025 → Q2 2025
| None this quarter. | |||
Portfolio Buys Q1 2025 → Q2 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q3 2025 | 4 | $55.6M | TRML, KRRO, JSPR, KZR |
| Q2 2025 | 6 | $23.6M | TRML, JSPR, KRRO, VTYX, HLVX |
| Q1 2025 | 6 | $23.1M | TRML, KRRO, JSPR, HLVX, VTYX |
| Q4 2024 | 6 | $51.1M | JSPR, TRML, KRRO, VTYX, HLVX |
| Q3 2024 | 6 | $51.4M | TRML, JSPR, KRRO, HLVX, VTYX |
| Q2 2024 | 6 | $52.6M | JSPR, KRRO, TRML, HLVX, VTYX |
| Q1 2024 | 6 | $89.7M | KRRO, JSPR, TRML, HLVX, VTYX |